Beijing Bohui Innovation Biotechnology Group Co Ltd
Beijing Bohui Innovation Biotechnology Group Co Ltd is a Chinese biotechnology company engaged in the research, development, and commercialization of innovative biopharmaceutical products.
Business. Beijing Bohui Innovation Biotechnology Group Co Ltd (300318.SZ) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the healthcare sector, focusing on product sales as its primary revenue model. Headquartered in Beijing, the company is listed on the Shenzhen Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Beijing Bohui Innovation Biotechnology Group Co Ltd (300318.SZ) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the healthcare sector, focusing on product sales as its primary revenue model. Headquartered in Beijing, the company is listed on the Shenzhen Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed.
The company's capital structure is characterized by a debt-to-equity ratio of 1.28, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.93, suggesting limited short-term liquidity to cover immediate obligations. Free cash flow is negative at -264.6 million CNY, and operating cash flow is also negative at -135.2 million CNY, reflecting ongoing cash outflows from operations.
Profitability metrics are weak, with a return on equity of -7.15% and a return on assets of -2.14%, both significantly below the industry median for pharmaceuticals. The company reported a net loss of 91.9 million CNY and an operating loss of 127.7 million CNY, indicating a lack of operational profitability. Gross profit of 293.9 million CNY is insufficient to cover operating expenses, contributing to the net loss.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financials. This lack of diversification increases exposure to market-specific risks, particularly in the Chinese pharmaceutical sector.
Growth trajectory is negative, with no disclosed revenue growth in the latest period. The company is expected to continue facing operational challenges in the near term, with no clear path to profitability in the current fiscal year. Capital expenditures of -156.9 million CNY suggest ongoing investment in infrastructure or R&D, but the negative free cash flow indicates that these investments are not yet generating returns.
Risk factors include medium liquidity risk due to the current ratio below 1 and a negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no recent or disclosed share issuance or at-the-market (ATM) programs. The company has not made any recent public filings or transcripts that would indicate material changes in strategy or operations.
- The company is operating at a net loss with negative free cash flow, indicating financial distress.
- A debt-to-equity ratio of 1.28 suggests a moderate reliance on debt financing.
- Return on equity and return on assets are both negative, indicating poor profitability.
- The company lacks geographic and segment diversification, increasing exposure to market-specific risks.
- Liquidity is a concern, with a current ratio of 0.93 and negative net cash after debt.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Beijing Bohui Innovation Biotechnology Group Co Ltd Market data — financials · 2026-05-26